MicroPulse Transscleral Laser Therapy: Short-term Clinical and Histological Impact on the Ocular Surface

eye (absence of light perception), or scleral thinning were also not included.Patients who withdrew their consent during the study were excluded.Detailed information about the benefits and potential risks of MicroPulse TLT was provided to each participant, as well as the specific objectives of obtaining conjunctival biopsy samples. IntroductIonMicroPulse transscleral laser therapy (TLT) has proved efficacious in lowering intraocular pressure (IOP) with a low incidence of complications in both primary and secondary forms of glaucoma.[1][2][3][4] Despite its therapeutic success, its effects on the human ocular surface have not been thoroughly investigated.This study sought to address this gap by evaluating the clinical and histopathological changes in the ocular surface following MicroPulse TLT. Methods Study PopulationThis prospective noncomparative study was conducted by the Departments of Ophthalmology and Anatomopathology at Mohamed Taher Maamouri University Hospital in Nabeul, Tunisia, over a period from January 2, 2023, to June 30, 2023.The study included individuals aged 18 years and above who had uncontrolled open-angle glaucoma despite maximal medical therapy, those with poor therapeutic adherence, or those with local or general intolerance to topical treatments.Patients with a history of ophthalmic or systemic conditions that might affect the conjunctiva, including symblepharon, ocular trauma, or previous eye surgeries, were not included in the study.Additionally, individuals with a previous history of TLT applied to the same eye, angle-closure glaucoma, active ocular inflammation, a nonfunctional